University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(SC)
Welcome,         Profile    Billing    Logout  
 7 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thomas, Sheeba
NCT00492050: Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Active, not recruiting
2
46
US
Bortezomib, Velcade, LDP-341, MLN341, PS-341, Rituximab, Rituxan, Valacyclovir, Valtrex
M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.
Waldenstrom's Macroglobulinemia
02/21
06/26
NCT01283997: Prevention of Treatment Induced Neuropathy in Multiple Myeloma

Completed
2
79
US
Placebo, Minocycline, Dynacin, Minocin, Minocin PAC, Myrac, Solodyn
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Myeloma
08/22
08/22
NCT02420860: Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
113
US
Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
04/25
04/25
NCT02960555: Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Active, not recruiting
2
61
US
Isatuximab, Hu 38SB19, Isatuximab-irfc, SAR 650984, SAR650984, Sarclisa, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
04/25
04/30
NCT02668731: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recruiting
1
60
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Dinaciclib, CDK Inhibitor SCH 727965, SCH 727965, Laboratory Biomarker Analysis
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma
06/17
 
NCT01209871: Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

Active, not recruiting
1
9
US
Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Lymphoplasmacytic Lymphoma
02/26
02/26
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Completed
1
46
US, RoW
APG2575 400 mg, APG2575 600 mg, APG2575 800 mg
Ascentage Pharma Group Inc.
Waldenstrom Macroglobulinemia
02/24
02/24
NCT01198067: Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Active, not recruiting
1
15
US
Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
04/25
04/25
Shah, Jatin J
No trials found

Download Options